Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
SUMMARY OF KEY EMPLOYMENT
BIOMED S NEW CHIEF EXECUTIVE OFFICER
SYDNEY, AUSTRALIA - As previously announced, the Board of Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) appointed Mr
Marc Voigt as CEO and Executive Director of the Company with effect from 9 July 2014.
In accordance with ASX listing rule 3.16.4, the material terms
of Mr Voigt s employment as CEO and Executive Director of Prima are provided below.
| Appointment | Mr Voigt s employment as CEO and Executive Director of Prima commenced on 9 July 2014. | |
| The initial term is for a period of 3 years. Each party is to provide at least 6 months notice of its intention to extend the term of the contract. | ||
| Base Remuneration | EUR 195,000 per annum, exclusive of statutory superannuation contributions. The base salary may be reviewed by the Chairman of Remuneration Committee or her nominee. | |
| Performance Incentives | Subject to obtaining any required or appropriate shareholder approvals, Mr Voigt will receive an LTI entitlement of up to AUD 500,000 in equity and an additional STI entitlement in the form of equity. He may also be offered an annual cash bonus of up to EUR 15,000. |
Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889
BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for
patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact:
Adam Holdsworth, ProActive Capital
(646) 862 4607; adamh@proactivecapital.com
Australia Investor/Media:
Mr Matthew Gregorowski, Citadel Communications
534 755; mgregorowski@citadelpr.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
905505-52; amuehlhaus@edicto.de
Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889